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Abstract
The heterogeneous nature of colorectal cancer (CRC) complicates
prognosis and is suggested to be a determining factor in the effi-
cacy of adjuvant therapy for individual patients. Based on gene
expression profiling, CRC is currently classified into four consensus
molecular subtypes (CMSs), characterized by specific biological
programs, thus suggesting the existence of unifying developmental
drivers for each CMS. Using human organoid cultures, we investi-
gated the role of such developmental drivers at the premalignant
stage of distinct CRC subtypes and found that TGFb plays an
important role in the development of the mesenchymal CMS4,
which is of special interest due to its association with dismal prog-
nosis. We show that in tubular adenomas (TAs), which progress to
classical CRCs, the dominating response to TGFb is death by apop-
tosis. By contrast, induction of a mesenchymal phenotype upon
TGFb treatment prevails in a genetically engineered organoid
culture carrying a BRAFV600E mutation, constituting a model system
for sessile serrated adenomas (SSAs). Our data indicate that TGFb
signaling is already active in SSA precursor lesions and that TGFb is
a critical cue for directing SSAs to the mesenchymal, poor-prognosis
CMS4 of CRC.
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Introduction
Transforming growth factor-b (TGFb) signaling controls a plethora
of physiological programs, influencing cellular behavior and tissue
homeostasis. The response to TGFb is highly context specific and
results in distinct or even opposite effects for different cell types
(Massague, 2012). The multifunctional nature of this cytokine can
also be observed in tumorigenesis, where it plays either a tumor-
suppressing or tumor-promoting role (Massague, 2008). Induction
of apoptosis, for example, by upregulation of the pro-apoptotic
molecule BIM and the death-associated protein kinase (DAPK) (Jang
et al, 2002; Ramesh et al, 2008; Heldin et al, 2009), as well as the
arrest of proliferation by the induction of cyclin-dependent kinase
inhibitors such as p21CIP1, are examples of tumor-suppressive
mechanisms (Hannon & Beach, 1994; Datto et al, 1995; Massague,
2008). On the other hand, tumors can benefit from activated TGFb
signaling due to its ability to enhance cancer cell invasion and
metastasis. The TGFb signaling molecule is a well-known inducer of
the epithelial–mesenchymal transition (EMT) (Moustakas & Heldin,
2007), a process during which epithelial-organized cells lose their
cell–cell junctions and gain a mesenchymal, migratory, and invasive
phenotype, allowing them to leave the primary site and spread to
distant organs (Thiery, 2002). Recent insight from murine models,
however, proposes that EMT may be related to therapy resistance
rather than enhanced metastatic spread (Fischer et al, 2015; Zheng
et al, 2015). Regardless of the exact mechanism, the mesenchymal
phenotype has been linked to dismal prognosis in patients for many
cancer types, including colorectal cancer (CRC) (Guinney et al,
2015). CRC samples can be classified into four distinct consensus
molecular subtypes (CMSs), of which CMS4 displays a
1 Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC),
University of Amsterdam, Amsterdam, The Netherlands
2 Cancer Genomics Center, Amsterdam, The Netherlands
3 Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Utrecht, The Netherlands
4 Department of Biomedical Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong
5 Department of Pathology, AMC, University of Amsterdam, Amsterdam, The Netherlands
6 Department of Gastroenterology, AMC, University of Amsterdam, Amsterdam, The Netherlands
7 Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany
8 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
*Corresponding author. Tel: +31 20 56 67777; E-mail: j.p.medema@amc.nl
†Present address: Centre for Tumour Biology, Barts Cancer Institute, University of London, London, UK
‡Present address: Department of Molecular Oncology, Genentech Inc., San Francisco, CA, USA
ª 2016 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 8 | No 7 | 2016 745
Published online: May 23, 2016 
mesenchymal gene expression profile and dismal clinical outcome
(Guinney et al, 2015).
Even though components of the TGFb signaling pathway are
often inactivated during CRC progression (Markowitz et al, 1995;
Fleming et al, 2013), it has been shown that active TGFb signaling—
judged by phosphorylation of the downstream components SMAD2/3
(phospho-SMAD2/3)—can be found in colorectal carcinomas
(Brunen et al, 2013). Tumors associated with poor prognosis
display significantly higher levels of phospho-SMAD2/3 also in the
tumor epithelium and activation of the TGFb pathway has been
linked to resistance to conventional and targeted chemotherapeutics
(Huang et al, 2012; Brunen et al, 2013).
For a long time, the development of CRC was thought to follow a
molecularly well-defined route with the inactivation of the adeno-
matous polyposis coli (APC) gene as the initiating event followed by
the activation of the KRAS oncogene and the inactivation of TP53 as
the tumor progresses to a metastatic carcinoma (Fearon & Vogel-
stein, 1990). The tubular adenoma (TA) was viewed as the main
epithelial precursor lesion to spawn colorectal malignancies (Muto
et al, 1975). However, over the last two decades, it has become
increasingly clear that the heterogeneity observed in colorectal
malignancies is also reflected already at the premalignant stage
(IJspeert et al, 2015). The classical path of CRC development and
progression has been complemented with the serrated neoplasia
pathway (Snover, 2011). Several types of serrated polyps have been
described (IJspeert et al, 2015), and the sessile serrated adenoma
(SSA) could be linked to malignant progression to CRC (Oono et al,
2009; Lash et al, 2010; IJspeert et al, 2015). Histologically and
molecularly SSAs present as distinct entities, characterized by a
serrated morphology and the activation of the BRAF oncogene
(Leggett & Whitehall, 2010; Snover, 2011). Furthermore, serrated
lesions often display DNA hypermethylation of CpG islands in
promoter regions, leading to silencing of tumor suppressor genes
(also known as the CpG island methylator phenotype or CIMP)
(Park et al, 2003; Kambara et al, 2004). Specific precursor lesions
have been suggested to develop into different types of CRC based on
gene expression profiling and SSAs were suggested to harbor the
potential to develop into the mesenchymal, poor-prognosis CRC
subtype, whereas TAs more closely relate to the chromosomally
instable type of CRC (De Sousa E Melo et al, 2013). However, it is
unclear what is responsible for promoting subtype-specific transfor-
mation and for installing unique features associated with distinct
groups of CRC. Gene expression-based characterization of a small
set of TA and SSA samples has allowed a glimpse of the wiring of
these polyps. Whereas components of the WNT pathway are highly
expressed in TAs, SSAs present with high levels of EMT- and TGFb
pathway-associated genes (De Sousa E Melo et al, 2013). Therefore,
we set out to determine the response of genetically distinct CRC
precursor lesions to TGFb stimulation in organoid cultures, model
systems that closely recapitulate human disease (van de Wetering
et al, 2015). We made use of human organoid cultures from normal
colon tissue and TA polyps, and the CRISPR (clustered regularly
interspaced short palindromic repeat)-Cas9 (CRISPR-associated
nuclease 9) system to genetically engineer an organoid culture to
carry the BRAFV600E mutation, thus modeling different paths of CRC
development. In TA organoids, which most frequently progress to
the classical CRC subtype, apoptosis was the dominating response
upon TGFb treatment, while induction of a mesenchymal phenotype
prevailed in the BRAFV600E-mutated organoid culture, presenting a
model system for the serrated path to CRC. SSAs following the
serrated neoplasia pathway have been suggested to harbor the
potential to progress either to good- or to poor-prognosis CRCs
based on molecular markers (Jass, 2007; Phipps et al, 2015).
Indeed, using gene expression data, we show that SSAs can be
segregated into both CMS1- and CMS4-like lesions, which is associ-
ated with activation of the TGFb pathway. Significantly higher levels
of TGFb pathway activity were detectable in SSAs predicted to
progress to CMS4-like CRCs compared to those poised to give rise to
CMS1 CRC. Hence, our data point to an important role of TGFb in
the serrated path of CRC development and propose that this cyto-
kine represents a critical cue in directing SSAs to the mesenchymal,
poor-prognosis CRC subtype.
Results
TGFb induces apoptosis in human tubular adenoma
organoid cultures
To study the effect of TGFb at an early stage of tumor development,
we obtained TAs from familial adenomatous polyposis (FAP)
patients, which would predictably follow the classical path of CRC
development (Fearon & Vogelstein, 1990; De Sousa E Melo et al,
2013). Organoid cultures (TA1–TA5) were established from these
premalignant lesions and they were propagated in medium without
the WNT-ligands WNT3A and R-Spondin-1 to select for transformed
cells in which the WNT pathway is constitutively active. Normal
non-transformed cells without activated WNT signaling do not
survive this selection process (Drost et al, 2015). Of note, besides
WNT pathway activation, one of the TA organoid cultures—TA1—
also carries a KRASG12V mutation (Appendix Fig S1A). In the classi-
cal path of CRC development, activating mutations in the KRAS
oncogene are thought to follow aberrant WNT pathway activation
(Fearon & Vogelstein, 1990); hence, the origin of the TA1 organoid
culture is likely to be a more advanced adenoma or early carcinoma.
The TGFb pathway was not perturbed in the TA organoid cultures,
as all five cultures used in this study showed SMAD4 expression
and induction of phopho-SMAD2 upon TGFb stimulation
(Appendix Fig S1B and C). In the organoid cultures TA2-TA5, the
formation of well-organized structures was disrupted by the addi-
tion of TGFb to the culture medium, leading to disintegration of the
organoids (Fig 1A). In the control condition, cleaved Caspase-3-
positive, and thus apoptotic, cells could only be found inside the
organoids (Fig 1B). These represent old cells that have been
replaced by a new generation, undergo apoptosis, and are shed into
the lumen. In contrast, the amount of cleaved Caspase-3-positive
cells was strongly increased upon TGFb treatment, highlighting the
loss of organization in these structures (Fig 1B). In contrast, the
KRAS-mutant TA1 organoid culture did not undergo apoptosis
judged by the lack of cleaved Caspase-3, but rather showed growth
arrest both morphologically and based on KI-67 expression (Figs 1A
and B, and EV1A). We performed gene expression arrays on control
and TGFb-treated samples of three TA organoid cultures and two
organoid cultures from normal colon tissue. As expected, genes
involved in apoptosis were highly enriched in the TGFb-treated
compared to the control samples judged by gene set enrichment
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Figure 1. TGFb induces an apoptotic response in human tubular adenoma (TA) organoids.
A The usually well-organized human TA organoids disintegrate upon TGFb stimulation (scale bars: 200 lm).
B Following TGFb treatment, TA organoid cultures display increased levels of cleaved Caspase-3 (scale bars: 200 lm).
C Gene expression profiles of TGFb-treated organoids show enrichment in apoptosis-related genes when compared to the control condition.
D The pro-apoptotic molecule BIM (BCL2L11) is upregulated in the TGFb-treated condition in all TA cultures, besides in TA1, which carries a KRASG12V mutation (one
representative of ≥ 3 independent experiments is shown, error bars represent SD).
Source data are available online for this figure.
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analysis (GSEA) (Mootha et al, 2003; Subramanian et al, 2005)
(Fig 1C). Similar results have previously been reported for mouse
intestinal organoids carrying an inactivating Apc mutation, in which
BCL2-like protein 11 (BCL2L11, BIM) was identified to mediate
TGFb-induced apoptosis (Wiener et al, 2014). Also in the human
TA organoid cultures, BIM was induced upon TGFb treatment
(Fig 1D), whereas BID and Puma (BBC3) were not induced or down-
regulated (Fig EV1A). All TA cultures displayed upregulation of
BIM, except the KRAS-mutated TA1 organoid culture (Fig 1D), con-
firming the previously published results that addition of a KRAS
mutation to an APC-mutated background increased resistance to
TGFb-mediated apoptosis by inhibiting the induction of BIM
(Wiener et al, 2014). Also human wild-type organoid cultures
isolated from normal colon mucosa did not show induction of BIM
and cleaved Caspase-3 upon TGFb treatment (Fig EV1B and C), but
slowed proliferation illustrated by reduction of KI-67 expression
(Fig EV1C). These results indicate that human cells with activated
WNT signaling respond to TGFb via induction of apoptosis, which
is alleviated in the presence of an oncogenic KRAS mutation. Thus,
patient-derived organoid cultures from premalignant lesions recapit-
ulate similar phenotypes upon TGFb stimulation as organoids from
genetically engineered mouse models (Wiener et al, 2014).
Human colon organoid cultures respond to TGFb by induction of
EMT features
TGFb is a well-known inducer of the EMT program (Moustakas &
Heldin, 2007). Indeed, we observed morphological changes in the
normal colon organoid cultures that resembled the induction of a
mesenchymal phenotype in these usually well-organized epithelial
structures (Fig 2A). Also in all five TA organoid cultures morpho-
logical changes indicative of EMT induction could be observed in
the surviving cells (Fig 2B and Appendix Fig S2A). Applying EMT
signatures to the gene expression data obtained from TGFb-treated
and control organoids revealed that genes present in these signa-
tures were enriched in TGFb-treated compared to control samples
(Fig 2C and Appendix Fig S2B) (Taube et al, 2010; Gro¨ger et al,
2012). In accordance, the EMT-inducing transcription factor zinc
finger E-box binding homeobox 1 (ZEB1) was upregulated upon
TGFb treatment in both normal colon and TA organoid cultures
(Fig 2D and E). Also the mesenchymal marker fibronectin 1 (FN1)
was strongly induced upon TGFb treatment (Fig 2F and
Appendix Fig S2C). Taken together, non-transformed as well as
transformed colon organoid cultures possess the ability to respond
to TGFb via the induction of the EMT program.
TGFb-treated human organoids adapt a mesenchymal CRC
subtype gene expression profile
Recently, CRC has been classified into multiple subtypes by several
groups (Cancer Genome Atlas Network, 2012; Perez-Villamil et al,
2012; Schlicker et al, 2012; Budinska et al, 2013; De Sousa E Melo
et al, 2013; Marisa et al, 2013; Sadanandam et al, 2013; Roepman
et al, 2014), and in a large international effort, the CRC subtyping
consortium (CRCSC) unified these classifications resulting in the four
consensus molecular subtypes (CMSs) of CRC (Guinney et al, 2015).
In line with the individual classifications, a mesenchymal subtype
(CMS4) was identified with significantly worse recurrence-free
survival (RFS) (Guinney et al, 2015). This subtype was characterized
by high expression of EMT-associated genes (De Sousa E Melo et al,
2013; Guinney et al, 2015). Additionally, based on gene expression
profiling SSAs were predicted to be potential precursor lesions of this
mesenchymal, poor-prognosis colon cancer subgroup (De Sousa E
Melo et al, 2013). Since the EMT phenotype—a hallmark of the
mesenchymal colon cancer subtype—can be induced by TGFb, and
the TGFb signaling pathway is predicted to be active based on gene
expression in CMS4 CRCs (Guinney et al, 2015) and SSAs (De Sousa
E Melo et al, 2013), we wondered whether TGFb might also dictate
subtype-specific gene expression. We chose FRMD6 (FERM domain
containing 6), a marker that is highly expressed in tumors of the
mesenchymal subtype, and caudal-type homeobox 2 (CDX2), which
is highly expressed in tumors of the classical group (De Sousa E Melo
et al, 2013) and assessed their expression changes upon TGFb treat-
ment. Normal colon and TA organoid cultures responded to TGFb
treatment with upregulation of FRMD6 (Fig 3A and B). CDX2 levels
were strongly reduced upon TGFb stimulation both on RNA and
protein level (Fig 3A–C and Appendix Fig S2D). A direct comparison
of the gene expression changes induced by TGFb in organoids with
either genes upregulated in CMS4 cancers (Fig 3D) or the 500 most
highly expressed genes in SSAs compared with TAs (Fig 3E) con-
firmed this switch to a more CMS4/SSA-like profile (Fig 3D and E).
Therefore, TGFb treatment of colon organoids not only induced
EMT, but also induced the expression of CMS4/mesenchymal marker
genes and downregulated expression of genes associated with the
classical, epithelial type of CRC.
SSA and TA polyps can be separated using a TGFb signature,
which is predictive of prognosis in CRC datasets
To gain further insight into the role of TGFb signaling at the early
stages of tumor development in vivo, we generated gene expression
data from a set of TA and SSA polyps (GSE45270 and GSE79460)
and analyzed the expression of the five most strongly induced and
five most strongly reduced genes upon TGFb treatment of TA orga-
noid cultures. The expression of these genes followed the expected
pattern, meaning genes induced upon TGFb treatment were more
highly expressed in SSAs, while the downregulated genes could be
detected at higher levels in TAs (Fig 4A). Applying an in vitro TGFb
response signature from TGFb-treated organoid cultures to gene
expression data from SSAs and TAs revealed that this signature was
able to segregate SSA from TA samples (Fig 4B). Additionally, this
epithelial cell-derived TGFb signature was capable of clustering
most of the CMS4 samples of the AMC-AJCCII-90 dataset apart from
CMS1-3 tumor samples (Fig EV2B) (GSE33113, De Sousa E Melo
et al, 2011). GSEA confirmed the higher expression of the TGFb
signature genes in SSA lesions and CMS4 tumors (Fig EV2A). As the
TGFb signature is able to identify CMS4 tumors that reportedly
display worse RFS (Guinney et al, 2015), we speculated that this
signature would be able to predict RFS. Indeed, our in vitro TGFb
response signature could predict RFS in two independent CRC
datasets (Fig EV2C). Importantly, the gene expression-based obser-
vations were substantiated by the finding that the TGFb target gene
ZEB1 was strongly expressed in the epithelium of SSA but not TA
polyps at the protein level (Fig EV3A).
Based on molecular markers, such as BRAF mutation and CIMP,
SSAs have previously been suggested to develop into two distinct
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Figure 2. TGFb stimulation of human colon organoids induces EMT features.
A, B Morphological changes in (A) normal colon (N1-3) and (B) surviving TA organoids upon TGFb treatment resemble the induction of a mesenchymal phenotype in
these usually well-organized epithelial structures (scale bars: 50 lm).
C Genes present in an EMT signature (Gröger et al, 2012) are enriched in TGFb-treated compared to control samples.
D, E The EMT-inducing transcription factor ZEB1 is strongly induced upon TGFb treatment both in (D) normal [one (representative) experiment is shown (n = 1 for N1
and N2, and n = 3 for N3), error bars represent SD] as well as (E) TA (one representative of ≥ 3 independent experiments is shown, error bars represent SD)
organoids.
F The mesenchymal marker fibronectin 1 (FN1) is induced following TGFb stimulation (scale bars: 200 lm).
Source data are available online for this figure.
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types of CRC, one associated with good and the other one with
poor prognosis (Jass, 2007; Phipps et al, 2015). Strikingly, we also
observed that the in vitro TGFb response signature derived from
organoids not only segregated TAs from SSAs, but also clustered
the SSA samples into two distinct groups (Fig 4B). This indicated


















































































































































Figure 3. TA organoids adapt their gene expression profiles to those of CMS4/SSA samples upon TGFb treatment.
A, B FRMD6 expression is strongly induced and CDX2 expression is downregulated both in (A) normal [one (representative) experiment is shown (n = 1 for N1 and N2,
and n = 3 for N3), error bars represent SD] and (B) TA (one representative of ≥ 3 independent experiments is shown, error bars represent SD) organoid cultures
following TGFb stimulation.
C The reduction in CDX2 levels in the TGFb-treated condition is also observed on the protein level (scale bars: 200 lm).
D, E Gene expression profiles of TGFb-treated samples show enrichment of genes highly expressed in (D) the mesenchymal CMS4 of CRC (log2FC > 2) and (E) SSA
precursor lesions when compared to control samples.
Source data are available online for this figure.
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as compared to the rest. To further study this distinction within
the SSA population, the CRC subtype affiliation of these lesions
was elucidated. CMS classification of the pre-neoplastic polyps
allowed us to predict that SSAs could indeed progress to either the
good-prognosis CMS1 (further referred to as CMS1-SSAs) or the
poor-prognosis CMS4 (Fig EV3B) and this perfectly aligned with
the segregation observed using the TGFb signature. This classifi-
cation also confirmed the link between TAs and the classical
CMS2, as almost all TA samples were classified into the CMS2
group (Fig EV3B; see Fig EV3C for KRAS and BRAF mutation as
well as CIMP status of these polyps). Intriguingly, the 4 SSAs that
predictably would give rise to carcinomas of the CMS4 (further
referred to as CMS4-SSAs) showed high expression of a subset of
genes present in the in vitro TGFb response signature (Fig 4B).
Indeed, the genes most strongly induced upon TGFb treatment and
differentially expressed between TAs and SSAs showed signifi-
cantly higher expression levels in CMS4-SSAs compared with
CMS1-SSAs (Fig 4C). Taken together, these data indicate that (i)
the TGFb pathway is operational in premalignant SSAs, that (ii)
SSAs are characterized by higher activity of TGFb signaling
compared to TAs, and that (iii) in CMS4-SSAs TGFb activity is
elevated even further, suggesting that high levels of TGFb signal-
ing direct SSAs to the CMS4 of CRC (Fig 4D).
A genetically engineered human organoid culture as model for
the serrated path to CRC
To further dissect the role of TGFb signaling in SSA precursor
lesions, we made use of a genetically engineered BRAFV600E-mutated
organoid culture. To date, we and others have not been successful
in establishing organoid cultures of SSAs (IJspeert et al, 2015), thus
rendering direct analysis of the role of TGFb signaling in these
precursor lesions in vitro impossible. The serrated path of CRC
development is thought to be initiated by a BRAFV600E mutation
(Snover, 2011). We therefore made use of the CRISPR (clustered
regularly interspaced short palindromic repeat)-Cas9 (CRISPR-asso-
ciated nuclease 9) system to genetically engineer an organoid
culture to carry a BRAFV600E mutation (Cho et al, 2013; Cong et al,
2013; Mali et al, 2013; Drost et al, 2015), thus modeling the serrated
path to CRC. Importantly, this organoid culture does not display
features of CIMP, yet, suggesting that it represents the earliest phase
of the serrated pathway. The organoid culture carrying the
BRAFV600E mutation did not respond to TGFb with apoptosis, judged
by the lack of cleaved Caspase-3 and BIM induction (Fig 5A–C). As
shown for normal and TA organoid cultures, the expression of the
pro-apoptotic genes BID and Puma was not induced upon TGFb
treatment (Appendix Fig S3A). Instead, the BRAFV600E-mutant orga-
noid culture showed decreased expression of KI-67, indicative of
growth arrest (Appendix Fig S3B). Additionally, TGFb treatment
induced a pronounced EMT-like phenotype in the BRAFV600E-mutant
organoid culture, coinciding with a marked upregulation of ZEB1
and FN1 (Fig 5D and E). Furthermore, the organoid culture carrying
the BRAFV600E mutation strongly induced FRMD6 and reduced the
expression of CDX2 (Fig 5F and G). These data indicate that lesions
carrying distinct genetic insults respond differentially to TGFb stim-
ulation early in tumor development: Whereas an apoptotic response
dominated in classical TAs, in both TA and BRAFV600E-mutated
organoids a robust EMT response was observed upon TGFb treat-
ment. In the case of TA organoids, a minority of cells that was able
to resist TGFb-induced cell death was selected for, survived this
stimulus, and underwent EMT. In contrast, the bulk of cells in the
BRAFV600E-mutant organoid culture survived treatment with TGFb
and the majority were able to induce the EMT process (Fig EV4). By
avoiding cell death upon stimulation with TGFb BRAFV600E-mutant
SSAs escape the detrimental effects of TGFb signaling and could
thus exploit TGFb pathway activation by the induction of the EMT
program. We therefore conclude that BRAFV600E mutations in
combination with a microenvironmental TGFb signal could be the
underlying pathway toward the induction of SSAs.
To further study the role of differential TGFb signaling between
CMS1-SSAs and CMS4-SSAs, gene expression profiles of the
BRAFV600E-mutant organoid culture in the absence and presence of
TGFb were generated (GSE79461). The TGFb response in the geneti-
cally engineered BRAFV600E-mutant organoid culture overlapped
significantly with that of TGFb-treated TA organoid cultures
(Fig EV5A), indicating that TGFb induces a similar cellular program
in our engineered model system as in organoids from precursor
lesions arisen in patients. In accordance with the previous observa-
tion using the TA TGFb signature, genes induced upon TGFb
treatment in the BRAFV600E-mutant organoid culture were highly
expressed in CMS4-SSAs compared to CMS1-SSAs and the most
strongly downregulated genes followed the opposite pattern
(Figs 5H and EV5B). Importantly, this distinction was maintained at
the carcinoma stage where BRAF-mutant CMS4 tumors showed
higher levels of TGFb-induced target genes compared to BRAF-
mutated CMS1 tumors and vice versa genes reduced upon TGFb
treatment displayed lower expression in BRAF-mutant CMS4 CRCs
compared to CMS1 CRCs (Figs 5I and EV5C). Taken together, these
data point to the fact that TGFb is indeed a critical cue to direct SSA
precursor lesions to the mesenchymal, poor-prognosis CMS4 of CRC
Figure 4. TGFb target genes are differentially expressed between TA and SSA samples.
A The five most strongly induced genes (right column) upon TGFb treatment of TA organoid cultures are higher expressed in SSAs when compared to TAs, whereas the
five most strongly reduced genes (left column) follow the opposite pattern (n = 12 for SSA and n = 15 for TA. The horizontal lines represent the mean, and the error
bars display the SD. P-values are based on unpaired two-tailed Student’s t-tests).
B Hierarchical clustering of 15 TA and 12 SSA samples using a TGFb response signature derived from TGFb-treated TA organoids (|log2FC| > 3). Expression values were
mean-centered (genewise), and cosine similarity was used as the distance measure.
C Genes induced upon TGFb treatment of TA organoids, which are differentially expressed between TA and SSA samples, display significantly higher expression levels in
CMS4-SSAs compared with CMS1-SSAs (n = 8 for CMS1-SSAs and n = 4 for CMS4-SSAs. The horizontal lines represent the mean, and the error bars display the SD.
P-values are based on unpaired two-tailed Student’s t-tests.).
D Gene expression-based classification reveals that SSAs could progress to CMS1 and CMS4 tumors. The data presented in this manuscript suggest that high activity of
the TGFb signaling pathway directs these precursor lesions to the CMS4 of CRC.
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Figure 5. A BRAFV600E-mutant organoid culture serves as model for the serrated path to CRC.
A An organoid culture genetically engineered using the CRISPR-Cas9 system to carry a BRAFV600E mutation represents a model for the serrated path to CRC. Upon
TGFb treatment, these culture gains a mesenchymal appearance (scale bars: 200 lm).
B, C TGFb stimulation does not induce (B) cleaved Caspase-3 or (C) BIM expression (n = 6) in the BRAFV600E-mutated organoid culture (scale bars: 200 lm; error bars
represent SD).
D, E Markers of the EMT program, (D) ZEB1 (n = 6) and (E) FN1 are strongly induced in the TGFb-treated condition (scale bars: 200 lm; error bars represent SD).
F, G FRMD6 is upregulated and CDX2 expression is reduced both on RNA (n = 6) as well as on protein level following TGFb stimulation (scale bars: 200 lm; error bars
represent SD).
H TGFb target genes downregulated upon TGFb treatment of the BRAFV600E-mutant organoid culture (TGFb down) are lower expressed in CMS4-SSAs compared to
CMS1-SSAs and genes induced by TGFb treatment (TGFb up) are more strongly expressed in CMS4-SSAs than in CMS1-SSAs (n = 4 for CMS4-SSAs and n = 8 for
CMS1-SSAs; FC = fold change).
I The differential expression of TGFb target genes observed for CMS1-SSAs and CMS4-SSAs is maintained at the carcinoma stage for CMS4 versus CMS1 BRAF-
mutant CRCs of the TCGA dataset (n = 4 for BRAF-mutant CMS4 and n = 34 for BRAF-mutant CMS1 CRC samples; FC = fold change).
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and offer a possible explanation as to how the same pre-neoplastic
lesion might spawn CRCs belonging to the most favorable and the
most dismal prognosis subtype.
Discussion
The roles of TGFb in CRC tumorigenesis are manifold and not undis-
puted in literature. While some studies indicate that the main target
of this growth factor is the tumor stroma due to unresponsiveness
of the malignant epithelium (Calon et al, 2012), others report that
active TGFb signaling can indeed be detected in epithelial tumor
cells (Brunen et al, 2013). Notwithstanding the exact mechanism of
action, increased levels of TGFb pathway activity are predictive of
prognosis and point to the presence of metastatic lesions (Friedman
et al, 1995; Robson et al, 1996; Tsushima et al, 2001; Calon et al,
2012; Brunen et al, 2013). This can in part be explained by the abil-
ity of TGFb to induce EMT, a process that is linked to poor disease
outcome (Shioiri et al, 2006; Spaderna et al, 2006). Two recent
reports enforce this notion and indeed associate the EMT program
with dismal outcome. The use of mouse models allowed the authors
of these studies for the first time to follow the EMT process in vivo
and suggests that the mesenchymal phenotype is not related to
metastatic dissemination, but to chemoresistance (Fischer et al,
2015; Zheng et al, 2015). While the mechanism by which EMT
confers poor prognosis is thus a matter of debate, it has been firmly
established that a mesenchymal cancer phenotype is linked to
dismal disease outcome. Indeed, gene expression-based classifi-
cation of CRC samples identified a mesenchymal subtype associated
with poor clinical outcome (Guinney et al, 2015). Despite the fact
that the CMSs of CRC cannot be identified based on unifying molec-
ular markers currently used in the clinic, they represent biologically
homogeneous groups, allowing the speculation that common under-
lying drivers are responsible for installing specific biological
programs. The activation of the EMT program is a hallmark feature
of the mesenchymal CMS4 of CRC and the TGFb signaling
pathway—a known inducer of this process (Moustakas & Heldin,
2007)—is predicted to be active in CMS4 tumors (Guinney et al,
2015). Therefore, we have herein elucidated the effect of TGFb on
subtype affiliation at the early stage of tumor development. We
show that the genetic background of pre-neoplastic lesions dictates
the dominating response to this signaling molecule, changing it from
a largely apoptotic response in WNT pathway-activated TAs to a
dominant EMT response in mitogen-activated protein kinase
(MAPK) pathway mutant cells. In addition, our data show that
TGFb influences subtype affiliation. Our data demonstrate that—
already in premalignant lesions—TGFb can induce the EMT
program. The severity of the simultaneously occurring apoptotic
response is strongly dependent on the genetic background: Whereas
it dominates in TAs, wild-type organoids and cultures with muta-
tions in the MAPK pathway are protected from apoptosis. Mutations
in the MAPK pathway in the form of activating KRAS mutations
occur during tumor progression in the classical path of CRC devel-
opment (Fearon & Vogelstein, 1990). In contrast, activation of this
pathway by the BRAFV600E mutation is an initiating mutation in the
serrated neoplasia pathway (Leggett & Whitehall, 2010; Snover,
2011). Since early SSA lesions can therefore exploit TGFb signaling
without dying by apoptosis, this growth factor is able to direct
subtype affiliation early in the developmental path of SSAs. Indeed,
our data indicate that high levels of TGFb signaling can poise SSA
lesions to develop to the mesenchymal CMS4 of CRC. Importantly,
TGFb stimulation led to downregulation of CDX2, whose expression
is low or absent in poor-prognosis, mesenchymal CRCs (De Sousa E
Melo et al, 2013). This observation has been re-enforced by a recent
study (Dalerba et al, 2016); however, it is not clear how and at what
stage in tumor progression CDX2 expression is lost. Our data
suggest that TGFb signaling downregulates CDX2 expression, possi-
bly early in tumor progression. Furthermore, the induction of an
EMT phenotype, which has been linked to the stem-like and thus
undifferentiated state (Mani et al, 2008), can be stimulated by TGFb
(Taube et al, 2010) and could therefore explain both low levels of
CDX2 expression and the immature phenotype of these cancer cells.
In contrast to apoptosis, the induction of growth arrest is not
influenced by the mutation status of the organoid cultures.
However, it is important to note that the genetically engineered
BRAFV600E-mutant organoid culture did not display a hypermethyla-
tion phenotype that is thought to be an early event in the serrated
path to CRC (Park et al, 2003; Kambara et al, 2004). Indeed, as
reported before, we observed methylation of the CDKN2A locus
(encoding for p16INK4A/p19ARF) in a panel of BRAFV600E-mutant
SSAs (data not shown), which is most likely installed to overcome
oncogene-induced senescence (Carragher et al, 2010). We speculate
that the epigenetic silencing of p16INK4A/p19ARF expression might
allow the cells to also circumvent the TGFb-induced growth arrest
and progress to a malignant stage. This hypothesis warrants further
testing with appropriate genetically engineered cultures.
It will be of interest to further investigate whether the premalig-
nant lesions progress to CRC while maintaining their TGFb-respon-
siveness or whether TGFb stimulation early in tumor development
installs a more aggressive phenotype without the constant need of
restimulation during progression. BRAFV600E-mutant CMS4 tumors
of the TCGA dataset display higher levels of TGFb pathway
activation based on gene expression compared with CMS1
BRAFV600E-mutant CRCs, suggesting that the distinction installed
early in tumor development is maintained at the carcinoma stage.
This long-term commitment may be explained by the fact that TGFb
can induce DNA hypermethylation (Papageorgis et al, 2010;
Davalos et al, 2012). DNA methylation represents a metastable
mechanism that can be inherited by daughter cells, allowing for
stabilization of specific phenotypes—such as EMT—without the
need for continuous signaling input. However, the organoid cultures
used in this study did not induce methylation of the miR-200
promoter regions upon TGFb treatment, which might be a reflection
of in vitro culture conditions. Specific requirements for the induction
of DNA hypermethylation in vivo might not be mimicked by in vitro
culture systems lacking microenvironmental components such as
cancer-associated fibroblasts (CAFs) and distinct extracellular
matrix components. Alternatively, even though CRCs frequently
contain mutations in TGFb pathway components (Markowitz et al,
1995; Fleming et al, 2013), cancer cells can maintain responsiveness
to the TGFb signaling molecule. It has, for instance, recently been
shown that instead of an overall insensitivity to TGFb, SMAD4 inac-
tivation leads to a shutdown of selective programs that would be
opposing malignant progression, such as apoptosis (David et al,
2016). Continuous TGFb signaling during tumor progression could
therefore install subtype affiliation early in the adenoma–carcinoma
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sequence and subsequently remain necessary to maintain it
throughout development.
To study the full response of SSAs to TGFb, their dependence
on this signaling molecule, and the dominating phenotype upon
stimulation, organoid cultures derived from these lesions are indis-
pensable. Thus far, we and others have not been able to establish
organoids from serrated adenomas (IJspeert et al, 2015). However,
the recent advances in genome editing using the CRISPR-Cas9
system have made it possible to engineer genetically defined orga-
noid cultures (Drost et al, 2015). Herein, we used this technique to
generate a BRAFV600E-mutant organoid culture to serve as an
in vitro model system for early serrated lesions. The fact that these
organoids have not progressed beyond the initial hit in the BRAF
gene, yet, allowed the elucidation of early events in the serrated
neoplasia pathway. Combining data from this model system with
gene expression-based information from SSA and TA samples
prompts us to hypothesize that TGFb plays a role in the serrated
pathway to CRC.
Our data indicate that high activity of the TGFb signaling path-
way can direct SSAs to the CMS4 of CRC, yet, the source of this
signaling molecule remains to be determined. Of note is the fact that
poor-prognosis CRCs display a stroma-rich environment (Calon
et al, 2015; Isella et al, 2015). One of the main stromal components
are CAFs, which have been described to secrete the TGFb signaling
molecule (Calon et al, 2014). Additionally, the abundant presence
of CAFs might provide a favorable environment for the premalig-
nant cells to overcome the TGFb-induced growth arrest and to
progress to a malignant, and eventually to a metastatic state.
Whereas TGFb is detrimental to the epithelium of TA precursor
lesions, SSAs might benefit from TGFb pathway activation, priming
them to adapt a more aggressive phenotype and directing these




Human tissues were obtained in accordance with the legislation in
the Netherlands. Collection of normal and adenomatous material
from the colon was approved by the Medical Ethical Committee
(normal tissue: 2014_178; adenomas: MEC 09/146 and MEC 05/071;
Academic Medical Center (AMC), Amsterdam). Tissue was collected
following written informed consent of patients, and the experiments
conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report.
Processing of TA and SSA samples
For RNA and gDNA extraction from patient material, 5 × 20 lm
frozen tissue sections were cut using a cryotome and stored at
80°C until further use. Fifteen TAs were obtained from 10 familial
adenomatous polyposis (FAP) patients, and 12 sessile serrated
adenomas (SSAs) were collected from 4 serrated polyposis
syndrome (SPS) patients. We confirmed the nature of each polyp by
H&E staining. RNA was extracted using the miRNAeasy micro kit
(Qiagen). Microarrays of these samples were performed as described
below, and the resulting gene expression profiles were analyzed in
combination with those described in (GSE45270, De Sousa E Melo
et al, 2013).
Organoid isolation, culture, and treatment
Human adenoma cultures TA1 and TA2 were derived from two
independent polyps of one patient and generated and maintained as
previously described (Sato et al, 2011; Prasetyanti et al, 2013). TA3-
TA5 organoid cultures were derived from polyps obtained from
three additional patients and established by cutting the polyps into
small pieces using tweezers and a scalpel. After washing, the pieces
were plated in growth factor-reduced BD matrigel matrix (BD
Biosciences, further referred to as matrigel) and mechanically disso-
ciated upon growth to propagate viable organoids [the naming of
the organoid cultures (TA1–TA5) is independent of the TA adenoma
samples used for gene expression array (TA2–TA16)]. Please see
Appendix Supplementary Methods for propagation and medium
composition.
Normal colon tissue was obtained from resection material of CRC
patients from a part of the mucosa ≥ 10 cm apart from the cancer-
ous tissue. Normal colon organoid cultures were isolated as previ-
ously described (Sato et al, 2011), and for a detailed description of
isolation, propagation, and medium composition, please see
Appendix Supplementary Methods.
The organoid cultures were treated with 5 ng/ml recombinant
human TGF-b 1 (PeproTech 100-21) for 5 days, and medium was
refreshed after 3 days. Control refers to TA culture medium + 1 lM
A83-01 + TGFb dissolvent, and to normal colon culture medi-
um + TGFb dissolvent (regular culture medium already contains
A83-01).
Organoid cultures were mycoplasma negative, as determined by
testing for mycoplasma contamination every 4–6 weeks.
Phase contrast pictures were taken with a Zeiss Axiovert 200M
fluorescence microscope.
Generation of the human BRAFV600E-mutant colon
organoid culture
The BRAFV600E mutation was introduced by homologous recombina-
tion in human colon organoids using a targeting vector containing a
puromycin-resistance cassette flanked by 50- (including the
BRAFV600E sequence) and 30-homology arms. The puromycin-
resistance cassette was targeted to the intron downstream of BRAF
exon 15. Organoids were cotransfected with a sgRNA targeting
BRAF (target sequence 50-TAG CTA CAG TGA AAT CTC GAT GG),
Cas9 endonuclease, and the targeting plasmid as described (Drost
et al, 2015). Growth medium was exchanged with medium contain-
ing 1 lg/ml puromycin 3 days after transfection. For clonal expan-
sion, single puromycin-resistant organoids were picked. Genotyping
was performed as previously described (Drost et al, 2015). Primer
sequences were as follows: BRAF-genotyping-forward: 50-GTT AGT
CAT GGG AAA GCT TC; BRAF-genotyping-reverse: 50-GCC TCC CCT
ACC CGG TAG AAT T. BRAFV600E-mutant organoids were cultured
in normal colon culture medium as described in the Appendix Sup-
plementary Methods and dissociated every 7 days, and the medium
was refreshed every 3–4 days.
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RNA extraction and quantitative real-time PCR
For RNA extraction from organoid cultures, matrigel was destroyed
mechanically and organoids were resuspended in cell recovery solu-
tion (BD Biosciences) and incubated on ice. Cells were pelleted, and
RNA was extracted using the NucleoSpin RNA II kit from Macherey-
Nagel.
To determine gene expression levels by qRT–PCR, total RNA was
reverse-transcribed to cDNA using Superscript III following the
manufacturer’s protocol (Invitrogen). qRT–PCR was performed
using SYBR Green (Roche) and a Roche Light Cycler 480 II in accor-
dance with the manufacturer’s instructions. All obtained values
were normalized to the expression of b-actin, and normalization to
B2M yielded similar results. Please see the Appendix Supplementary
Methods for primer sequences.
Western blotting
To prepare protein lysates, matrigel was mechanically disrupted and
resuspended in PBS. Organoids were pelleted and washed once with
PBS. Organoids were resuspended in 1X reducing sample buffer, and
lysates were sonicated and boiled for 5 min at 85°C. Protein concen-
tration was determined using the Protein Quantification Assay from
Macherey-Nagel. Ten micrograms of protein was loaded on 4–15%
Mini-PROTEAN TGXTM Precast Protein Gels (Bio-Rad) and trans-
ferred to a hydrophobic, microporous, polyvinylidene difluoride
(PVDF) membrane with a pore size of 0.2 lm (Roche). Membranes
were blocked for 1 h in 5% bovine serum albumin in PBS + 0.2%
Tween-20 (Sigma) and subsequently incubated in primary antibody
dilution in 5% bovine serum albumin in PBS + 0.2% Tween-20 at
4°C overnight [anti-phospho-Smad2 (Ser465/467) (138D4) (1:2,000,
Cell Signaling 3108); anti-Smad2 (L16D3) (1:2,000, Cell Signaling
3103)]. The secondary antibody in 5% bovine serum albumin in
PBS + 0.2% Tween-20 [anti-rabbit-HRP (1:2,000 Cell Signaling
7074); anti-mouse-HRP (1:10,000, Southern Biotech 1070-05)] was
applied for 1 h at room temperature. After washing, the membrane
was developed using Lumi-LightPLUS Western Blotting Substrate
(Roche), and signal was detected with the ImageQuant LAS4000 (GE
Healthcare Life Sciences). Washing steps were performed using
PBS + 0.2% Tween-20.
Immunohistochemistry
For immunohistochemical stainings, the matrigel cultures were
washed twice with PBS and fixed using 4% paraformaldehyde (Klin-
ipath) overnight at 4°C. Subsequently, paraformaldehyde was
replaced with 70% ethanol. After an incubation period of 30 min at
RT, cells were incubated for 30 min at RT in 96% ethanol contain-
ing hematoxylin to visualize the organoids. Dehydration was
continued with 100% ethanol followed by xylene each twice for
30 min at RT. Subsequently cells were incubated in paraffin at 60°C
twice for 30 min, followed by embedding in paraffin.
Four-micrometer sections of formalin-fixed paraffin-embedded
organoids were used for immunohistochemistry.
CDX2, SMAD4, FN1: After rehydration, antigen retrieval was
performed using a 10 mM sodium citrate buffer at pH 6.0 (Vector
Laboratories) for 20 min at 98°C. Endogenous peroxidase was
blocked with 3% H2O2 (VWR) in PBS for 15 min at RT followed by
incubation in ultraV block (Immunologic) for 10 min at RT. Sections
were incubated in primary antibody dilution at 4°C overnight [anti-
CDX2 (1:100, BioGenex, clone CDX2-88, MU392A); anti-SMAD4
(B-8) (1:400, Santa Cruz Biotechnology sc-7966); anti-Fibronectin
Clone 10/Fibronectin (1:100, BD Biosciences 610077)]. Subse-
quently, post-antibody blocking (Immunologic) was added for
20 min at RT followed by poly-HRP-anti-mouse/rabbit/rat IgG
(Immunologic) for 30 min at RT. Washing steps were performed
using PBS. Sections were incubated in Bright DAB solution
(Immunologic), rinsed in dH2O, and counterstained using hema-
toxylin (Klinipath). After dehydration, slides were mounted using
Pertex (HistoLab). Images were taken with a Leica TCS-SP2.
ZEB1: Same as the immunohistochemistry protocol for CDX2,
SMAD4, FN1 above, with the exception of antigen retrieval:
performed using an EDTA-based buffer at pH 9.0 (Vector Laborato-
ries) for 20 min at 98°C. Sections were incubated in primary antibody
dilution at 4°C overnight [anti-ZEB1 (1:400, Sigma HPA027524)].
Cleaved Caspase-3 (Asp175): After rehydration, antigen retrieval
was performed using a 10 mM sodium citrate buffer at pH 6.0 (Vector
Laboratories) for 30 min at 95°C. Endogenous peroxidase was
blocked with 3% H2O2 (VWR) in methanol for 20 min at RT followed
by incubation in ultraV block (Immunologic) for 5 min at RT.
Sections were incubated in primary antibody dilution at 4°C over-
night [anti-cleaved Caspase-3 (Asp175) (1:200, Cell Signaling 9661)].
Subsequently, poly-HRP-anti-mouse/rabbit/rat IgG (Immunologic)
was added for 60 min at RT. Washing steps were performed using
PBS + 0.05% Tween-20. Sections were incubated in Bright DAB
solution (Immunologic), rinsed in dH2O, and counterstained using
hematoxylin (Klinipath). After dehydration, slides were mounted
using Pertex (HistoLab). Images were taken with a Leica TCS-SP2.
Mutation analysis
gDNA was extracted from the TA organoid cultures and from match-
ing samples of 18 patient-derived adenoma samples for which gene
expression profiles were derived using the NucleoSpin Tissue kit from
Macherey-Nagel. BRAF, KRAS, NRAS, and PIK3CA mutations were
analyzed using two multiplex PCRs as described before (Lurkin et al,
2010). The TA1 organoid culture was subjected to PCR followed by
direct Sanger sequencing to confirm the KRAS mutation. Amplification
of exon 2 of the KRAS gene was carried out in a 25 ll total reaction
volume consisting of 20 ng gDNA, 12.5 ll Reddymix (Thermo Scien-
tific), 1 ll forward and reverse primers (10 lM), and 6.5 ll H2O.
Samples were subjected to 5 min 95°C, 40 cycles of 30 s 95°C, 30 s
55°C, 1 min 30 s 72°C, followed by 5 min 72°C. One microliter of
PCRs was subsequently sequenced using BigDye Terminator 3.1
(BDT, Applied Biosystems). Primer sequences: KRAS_exon2-forward:
50-GTG TGA CAT GTT CTA ATA TAG TCA; KRAS_exon2-reverse:
50-GAA TGG TCC TGC ACC AGT AA. Please see the Appendix Supple-
mentary Methods for analysis of the BRAF mutation and CIMP status
of patient-derived adenoma samples.
Nicoletti assay
Matrigel was destroyed mechanically, and organoids were resus-
pended in cell recovery solution (BD Biosciences) and incubated on
ice. Cells were pelleted and resuspended in Nicoletti buffer (0.1%
sodium citrate (w/v) and 0.1% Triton X-100 (v/v) in deionized
EMBO Molecular Medicine Vol 8 | No 7 | 2016 ª 2016 The Authors
EMBO Molecular Medicine TGFb directs subtype affiliation of CRC precursor lesions Evelyn Fessler et al
756
Published online: May 23, 2016 
water pH 7.4, supplemented with 50 lg/ml propidium iodide before
use) (Nicoletti et al, 1991). After incubation at 4°C, PI staining of
nuclei was analyzed using flow cytometry (FACS Canto). Measure-
ments were performed in triplicate for each cell line and condition,
and the experiment was repeated at least three independent times.
Microarray
Microarrays of TA, normal, and BRAFV600E-mutant organoid cultures
as well as patient-derived TA and SSA samples were performed
using the GeneTitanTM MC system from Affymetrix according to the
standard protocols of the Cologne Center for Genomics (CCG),
University of Cologne, Germany. Three TA, two normal colon, and
the genetically engineered BRAFV600E-mutant organoid cultures were
included in the microarray, and the replicates included in the
microarray were as follows: TA1 control n = 1, + TGFb n = 1; TA2
control n = 2, + TGFb n = 4; TA3 control n = 2, + TGFb n = 1; N2
and N3 control n = 1, + TGFb n = 1; BRAFV600E control n = 3, +
TGFb n = 2; patient-derived TA n = 9 and SSA n = 7. Only samples
with an RNA integrity number (RIN) above 7 were included.
Microarray data can be viewed online under GEO accession number
GSE79462 [comprising microarrays of patient-derived adenomas
(GSE79460) and organoid cultures (GSE79461)].
Gene expression data
The microarray data were normalized and summarized using robust
multiarray analysis (rma) (Irizarry et al, 2003), and batch effects
were removed using the Combat algorithm (Johnson et al, 2007) as
implemented in the sva R package (R package version 3.18.0). After
normalization, the probe sets were annotated using the hgu133-
plus2.db annotation package [Affymetrix Human Genome U133
Plus 2.0 Array annotation data (chip hgu133plus2) R package
version 3.1.3]. In case of multiple probe sets interrogating a specific
gene, the probe set with the highest mean intensity was selected as
representative for that gene.
TGFb signature
A TGFb signature was established by comparing gene expression
following TGFb and control treatment in three TA organoid cultures.
Genes differentially expressed between TGFb and control treatment
were identified using the limma R package (Ritchie et al, 2015) in
which both the treatment and organoid culture-specific effects were
modeled. Genes with a P-value < 0.01 (adjusted for multiple testing
using the Benjamini & Hochberg method) and an absolute log2 fold
change > 3 were selected to be part of the TGFb signature (231
genes). The same approach was used to determine a TGFb signature
in the genetically engineered BRAFV600E-mutant organoid culture
(334 genes).
Gene set enrichment analysis
Gene set enrichment analyses (GSEAs) (Mootha et al, 2003;
Subramanian et al, 2005) were performed using the default settings
of the Broad Institute’s web application tool (http://www.broadinsti
tute.org/gsea/index.jsp). P-values indicating the significance of
enrichment were estimated by 1,000 permutations. The following
publicly available signatures were used: an apoptosis signature
(KEGG) and two EMT signatures (Taube et al, 2010; Gro¨ger et al,
2012). Furthermore, we applied a signature comprising genes upreg-
ulated in CMS4 compared to CMS2 + 3 tumor samples of the AMC-
AJCCII-90 dataset (log2FC > 2, GSE33113), the 500 most highly
expressed genes in SSA compared with TA samples (GSE45270), a
signature of genes induced upon TGFb treatment in TA organoids
(log2FC > 3; described above), and a signature of genes induced
upon TGFb treatment in the BRAFV600E organoid culture
(log2FC > 3; described above).
Molecular subtype classification of adenomas
Microarray data for the two batches of adenoma samples, newly
generated and from (De Sousa E Melo et al, 2013), were first sepa-
rately normalized and summarized using the RMA method (Irizarry
et al, 2003). Non-biological effects between the two batches were
detected using principal component analysis and were corrected
using ComBat (Johnson et al, 2007). The corrected expression pro-
files were collapsed from probe sets to unique genes and median-
centered across all samples. The classifier (Guinney et al, 2015)
developed by the colorectal cancer subtyping consortium (CRCSC)
was then employed to classify adenoma samples into consensus
molecular subtypes. Only samples that could be classified with a
posterior probability of ≥ 0.5 were included in the subsequent
The paper explained
Problem
Colorectal cancer (CRC) is a heterogeneous disease, which hampers
accurate prognostication and the efficacy of adjuvant therapy.
Recently, gene expression-based classification has allowed the identifi-
cation of four consensus molecular subtypes (CMSs) of CRC and
samples belonging to each group are defined by common biological
programs. However, to date it is not clear what is responsible for driv-
ing the development to one specific CMS. Of special interest is the
mesenchymal CMS4 as patients in this group present with dismal
prognosis. Gene expression data point to a role of transforming
growth factor-b (TGFb) in this subset of CRC and in its associated
premalignant lesion, the SSA.
Results
We studied the effect of TGFb at the premalignant stage of CRC
development. We made use of organoid cultures from normal colon
epithelium, (TAs; precursor lesions of the classical, good-prognosis
CMS), and of an organoid culture genetically engineered to carry a
BRAFV600E mutation, which frequently occurs early in the serrated path
to CRC. Our data show that an apoptotic phenotype prevailed in TA
organoids upon TGFb treatment, whereas cultures from normal
epithelium and from material carrying an activating mutation in the
MAPK pathway were protected from apoptosis induction. TGFb stimu-
lation of organoid cultures led to the induction of a mesenchymal
phenotype and they adapted their gene expression profiles to those of
SSAs and the mesenchymal CMS4.
Impact
Our data on premalignant lesions of CRC indicate that distinct genetic
backgrounds respond differentially to TGFb treatment and that SSAs
might benefit from TGFb stimulation. We hypothesize that high levels
of TGFb signaling activity install a mesenchymal phenotype in these
distinct CRC precursor lesions, directing them to the mesenchymal,
poor-prognosis CRC subtype.
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analyses and their gene expression profiles are available at GEO:
GSE45270 (TA: GSM1100484-GSM1100489 and SSA: GSM1100491-
GSM1100495) and GSE79460.
Survival analysis
The association of the TGFb signature with recurrence-free survival
was tested using two publicly available colon tumor gene expression
datasets [GSE33113 (De Sousa E Melo et al, 2011) and TCGA-COAD
Illumina HiSeq and genome analyzer (GA) (http://cancergenome.
nih.gov/)]. Stage IV patients were excluded from the TCGA dataset
for this analysis. The samples in both datasets were divided into
TGFb signature low and high groups using the Pearson correlation
with the 231-gene TGFb signature derived from the TA organoid
cultures. Samples with a correlation > 0.1 were assigned to the
TGFb high group and samples with a correlation < 0.1 to the TGFb
low group. The survival distributions of the two groups were
compared with the log-rank test.
Statistics
The log-rank test was used to compare the RFS of different groups
shown in the KM plots. The Pearson’s correlation test makes use of
a t distribution with number of observations -2 degrees of freedom
to determine a P-value. For all other comparisons, unpaired two-
tailed Student’s t-tests were used. If not otherwise indicated,
mean  SD is depicted. Experiments with TA and BRAFV600E-
mutant organoid cultures were performed at least three independent
times, of which one representative experiment is depicted in the
figures (if not otherwise indicated in the figure legend). Due to the
limited life span of normal colon organoid cultures, experiments
with N1-N3 organoids could not all be performed three independent
times (N3 qRT–PCR n = 3, N3 IHC n = 2, and N1 + N2 qRT–PCR
n = 1). A P-value of below 0.05 was considered significant.
Expanded View for this article is available online.
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